Outcomes of antifungal prophylaxis in high-risk liver transplant recipients
dc.contributor.author | Hadley, S. | en_US |
dc.contributor.author | Huckabee, C. | en_US |
dc.contributor.author | Pappas, Peter G. | en_US |
dc.contributor.author | Daly, J. | en_US |
dc.contributor.author | Rabkin, John M. | en_US |
dc.contributor.author | Kauffman, C. A. | en_US |
dc.contributor.author | Merion, Robert M. | en_US |
dc.contributor.author | Karchmer, A. W. | en_US |
dc.date.accessioned | 2010-06-01T18:26:12Z | |
dc.date.available | 2010-06-01T18:26:12Z | |
dc.date.issued | 2009-02 | en_US |
dc.identifier.citation | Hadley, S.; Huckabee, C.; Pappas, P.G.; Daly, J.; Rabkin, J.; Kauffman, C.A.; Merion, R.M.; Karchmer, A.W. (2009). "Outcomes of antifungal prophylaxis in high-risk liver transplant recipients." Transplant Infectious Disease 11(1): 40-48. <http://hdl.handle.net/2027.42/71644> | en_US |
dc.identifier.issn | 1398-2273 | en_US |
dc.identifier.issn | 1399-3062 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/71644 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19144094&dopt=citation | en_US |
dc.description.abstract | Antifungal prophylaxis for liver transplant recipients (LTRs) is common among patients considered at high risk of infection, but optimal prophylaxis duration and drug has not been defined. This study aimed to assess the effects of 14 days of antifungal therapy prophylaxis in reducing proven invasive fungal infections (IFI) in high-risk subjects. Eligible subjects who met 2 or more risk criteria were randomized 1:1 to the treatment arms (liposomal amphotericin B or fluconazole) and were followed for 100 days post transplantation for evidence of IFI. The study was designed to enroll 300 subjects, but was closed early for insufficient enrollment. A total of 71 subjects were enrolled and randomized. Two-thirds of subjects completed 14 days of study therapy. Ten subjects developed proven or probable IFI with Candida species (9 subjects) and Cryptococcus neoformans (1 subject); rates were similar in the 2 treatment arms. Eleven subjects died, but no death was attributed to study drug or IFI. In summary, high-risk LTRs tolerated antifungal prophylaxis well, and rates of IFI were lower than previously reported in untreated high-risk LTRs. | en_US |
dc.format.extent | 201283 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.rights | © 2009 John Wiley & Sons A/S | en_US |
dc.subject.other | Fungal Infections | en_US |
dc.subject.other | Liver Transplantation | en_US |
dc.subject.other | Prophylaxis | en_US |
dc.subject.other | Liposomal Amphotericin B | en_US |
dc.subject.other | Fluconazole | en_US |
dc.subject.other | Antifungal | en_US |
dc.title | Outcomes of antifungal prophylaxis in high-risk liver transplant recipients | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan Medical Center and Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA , | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan, USA , | en_US |
dc.contributor.affiliationother | Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA , | en_US |
dc.contributor.affiliationother | Bacteriology and Mycology Biostatistics and Operations Unit, Rho Federal Systems Division Inc., Chapel Hill, North Carolina, USA , | en_US |
dc.contributor.affiliationother | Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA , | en_US |
dc.contributor.affiliationother | Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA , | en_US |
dc.contributor.affiliationother | Department of Surgery, Section of Liver Transplantation at Oregon Health and Sciences University in Portland, Oregon Health and Sciences University, Portland, Oregon , | en_US |
dc.contributor.affiliationother | Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA | en_US |
dc.identifier.pmid | 19144094 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/71644/1/j.1399-3062.2008.00361.x.pdf | |
dc.identifier.doi | 10.1111/j.1399-3062.2008.00361.x | en_US |
dc.identifier.source | Transplant Infectious Disease | en_US |
dc.identifier.citedreference | Wajszczuk CP, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347 – 353. | en_US |
dc.identifier.citedreference | Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine 1988; 67: 132 – 143. | en_US |
dc.identifier.citedreference | Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126: 149 – 156. | en_US |
dc.identifier.citedreference | Paya CV. Fungal infection in solid-organ transplantation. Clin Infect Dis 1993; 16: 677 – 688. | en_US |
dc.identifier.citedreference | Fung JJ. Fungal infection in liver transplantation. Transpl Infect Dis 2002; 4: 18 – 23. | en_US |
dc.identifier.citedreference | Gayowski T, Marino IR, Singh N, et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1998; 65: 499 – 504. | en_US |
dc.identifier.citedreference | Rabkin JM, Oroloff SL, Corless CL, et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 2000; 179: 426 – 430. | en_US |
dc.identifier.citedreference | Collins LA, Samore MH, Roberts MS, et al. Risk factors for early invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644 – 652. | en_US |
dc.identifier.citedreference | Viviani MA, Tortorano AM, Malaspina C, et al. Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis. Eur J Epidemiol 1992; 8: 433 – 436. | en_US |
dc.identifier.citedreference | Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 1995; 21: 1328 – 1336. | en_US |
dc.identifier.citedreference | Patel R, Portela D, Bradley AD, et al. Risk factors of invasive Candida and non- Candida fungal infections after liver transplantation. Transplantation 1996; 62: 926 – 934. | en_US |
dc.identifier.citedreference | Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial. Transplant Proc 1995; 27: 1195 – 1198. | en_US |
dc.identifier.citedreference | Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 729 – 737. | en_US |
dc.identifier.citedreference | Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002; 74: 688 – 695. | en_US |
dc.identifier.citedreference | Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990's. Transplantation 1997; 64: 716 – 720. | en_US |
dc.identifier.citedreference | Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59: 851 – 859. | en_US |
dc.identifier.citedreference | Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46 – 52. | en_US |
dc.identifier.citedreference | Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75: 2023 – 2029. | en_US |
dc.identifier.citedreference | Karchmer AW, Samore MH, Hadley S, Collins LA, Jenkins RL, Lewis WD. Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc 1995; 106: 38 – 48. | en_US |
dc.identifier.citedreference | Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006; 6: 386 – 391. | en_US |
dc.identifier.citedreference | Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7 – 14. | en_US |
dc.identifier.citedreference | Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transpl recipients. Cochrane Database Syst Rev 2004; CD004291. | en_US |
dc.identifier.citedreference | Fortun J, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8: 1065 – 1070. | en_US |
dc.identifier.citedreference | Tollemar J, Ringden O, Andersson S, Sundberg P, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577 – 582. | en_US |
dc.identifier.citedreference | Zwaveling JH, Maring JK, Klompmaker IJ, et al. Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit Care Med 2002; 30: 1204 – 1209. | en_US |
dc.identifier.citedreference | Lumbreras C, Cuervas-Mons V, Jara P, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174: 583 – 588. | en_US |
dc.identifier.citedreference | Singhal S, Ellis RW, Jones SG, et al. Targeted prophylaxis with amphotericn B lipid complex in liver transplantation. Liver Transpl 2000; 6: 588 – 595. | en_US |
dc.identifier.citedreference | Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 1995; 59: 45 – 50. | en_US |
dc.identifier.citedreference | Nieto-Rodriguez JA, Kusne S, Manez R, et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996; 233: 70 – 76. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.